Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacogenomics Firm Genetika+ Raises $10M in Series A Round

NEW YORK — Israeli pharmacogenomics firm Genetika+ said on Thursday that it has raised $10 million in a Series A financing round.

The round was led by GreyBird Ventures with participation from Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, and individual investors Howard Morgan and Michael Zeisser.

Genetika+ is developing a test that uses blood-based neurological biomarkers and a patient's genetic and medical history to predict the best antidepressant drug or drug combination for that individual. The company also offers a service to help depression drug developers predict drug responses in patient groups.

Genetika+ said it will use the Series A funding to expand clinical trials of its technology, increase its manufacturing capabilities, and establish a clinical lab in Boston, as well as add employees in Israel and the US.

"Millions of patients around the world face an arduous journey to find the most effective medication to treat their depression," Genetika+ cofounder and CEO Talia Cohen Solal said in a statement. "We're excited to secure this funding, which will enable the first biologically relevant measures to inform potentially life-changing medication selection decisions."